Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)

NCT05668962 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05668962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05668962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: a Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
March 1, 2023
Completion date
January 1, 2026
Enrollment
30 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

follicular thyroid cancer, metastatic thyroid cancer, papillary thyroid cancer, thyroid cancer, thyroid carcinoma, unresectable thyroid gland carcinoma